Tara L. Sedlak

Tara L. Sedlak

Auto-generated profile, based on publicly available information

Tara L. Sedlak

University of British Columbia

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2016 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
ERErin Rayner‐Hartley
Erin Rayner‐Hartley
TSTara Sedlak
Tara Sedlak
Ranolazine, a piperazine derivative sold under the trade name Ranexa, is a well‐tolerated medication that selectively inhibits the late sodium current. Additionally, ranolazine has beneficial metabolic properties and does not affect heart rate or blood pressure. Ranolazine is currently approved in

15 September 2022 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
IKIsabel Kim
Isabel Kim
TFThalia S. Field
Thalia S. Field
DWDarryl Wan
Darryl Wan
KHKarin Humphries
Karin Humphries
TSTara Sedlak
Tara Sedlak

1 April 2018 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
MPMahraz Parvand
Mahraz Parvand
ERErin Rayner-Hartley
Erin Rayner-Hartley
TSTara Sedlak
Tara Sedlak

6 September 2022 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
MPMahraz Parvand
Mahraz Parvand
LCLily Cai
Lily Cai
SGSiavash Ghadiri
Siavash Ghadiri
KHKarin H. Humphries
Karin H. Humphries
ASAndrew Starovoytov
Andrew Starovoytov
TSTara L. Sedlak
Tara L. Sedlak

1 March 2020 in American Journal of Therapeutics
Verified
Journal Article
Closed access
ERErin Rayner-Hartley
Erin Rayner-Hartley
MPMahraz Parvand
Mahraz Parvand
KHKarin H. Humphries
Karin H. Humphries
ASAndrew Starovoytov
Andrew Starovoytov
JPJulie E. Park
Julie E. Park
TSTara Sedlak
Tara Sedlak
Background: Ranolazine is approved in the United States and Europe for chronic stable angina. Microvascular angina (MVA) is defined as angina with no obstructive coronary artery disease. Study Question: Our objective was to assess the effectiveness of ranolazine at improving angina scores and quality of life in a Canadian cohort with severe refractory angina due to MVA. Study Design: We administered questionnaires to 31 patients at baseline and after at least 6 weeks of ranolazine treatment. Measures and Outcomes: Validated, clinically significant changes for each Seattle Angina Questionnaire domain and the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form were obtained from the literature. Score changes between baseline and postranolazine use were analyzed using sign test. Results: Patients were mostly female (27 of 31 patients) with a median age of 57 years. After initiation of ranolazine treatment, patients experienced improvements in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form scores (80.6%; P < 0.01) and in 3 of the 4 domains of the Seattle Angina Questionnaire (physical limitation: 73.3%; P = 0.02; treatment satisfaction: 80.6%; P < 0.01; and disease perception: 77.4%; P < 0.01). Patients were less likely to have interactions with the health care system after ranolazine treatment as compared with before (35.5% vs. 93.5%; P < 0.01). Conclusions: Ranolazine significantly improves symptom control and quality of life in patients with MVA and severe refractory angina and reduces their interaction with the health care system. Given the potentially debilitating effect of chronic angina in MVA, ranolazine may be an effective treatment option.

1 September 2017 in Journal of Women's Health
Verified
Journal Article
Closed access
SGShannon Galway
Shannon Galway
FAFalisha Adatia
Falisha Adatia
MGMaja Grubisic
Maja Grubisic
MLMay Lee
May Lee
PDPatrick Daniele
Patrick Daniele
TSTara L. Sedlak
Tara L. Sedlak
Background: Treatment of patients with stable angina and nonobstructive coronary artery disease (CAD) has not been well characterized. We comparatively evaluated medication use in males and females with stable angina with no CAD, nonobstructive CAD, and obstructive CAD. Methods: We studied all patients ≥20 years old with stable angina undergoing coronary angiography in British Columbia (BC), Canada, from January 2008 to March 2010 (n = 7,535). No CAD, nonobstructive CAD, and obstructive CAD were defined as 0%, 1%–49%, and ≥50% luminal narrowing in any epicardial coronary artery, respectively. Medication use, 3 months before and 3 months following angiography, was obtained through BC PharmaNet for angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), beta-blockers, statins, antiplatelet agents, and prescriptions for all three ACE-I/ARBs, beta-blockers, and statins (combination therapy). Results: Following angiography, patients with no and nonobstructive CAD had significantly lower rates of prescription use of all medications, including combination therapy, than patients with obstructive CAD (p < 0.001). Use of ACE-I/ARBs, beta-blockers, statins, and combination therapy did not differ by sex, but females had higher use of CCB in all CAD groups, and clopidogrel in nonobstructive and obstructive CAD groups, compared to males. Conclusions: In patients with stable angina, medication use following angiography is low in nonobstructive CAD with only 58.9% prescribed a statin and 19.4% on combination therapy at 3 months. There are no important sex differences in medication use in any CAD category post-angiography. Future studies should explore methods of improving quality of care in patients with nonobstructive CAD.